上证 50 指数样本调整名单： | 调出名单 | | 调入名单 | | | --- | --- | --- | --- | | 证券代码 | 证券名称 | 证券代码 | 证券名称 | | 600010 | 包钢股份 | 600150 | 中国船舶 | | 600196 | 复星医药 | 601601 | 中国太保 | | 600745 | 闻泰科技 | 601988 | 中国银行 | | 601066 | 中信建投 | 688041 | 海光信息 | | 603260 | 合盛硅业 | 688981 | 中芯国际 | 上证 180 指数样本调整名单： | | 调出名单 | | 调入名单 | | --- | --- | --- | --- | | 证券代码 | 证券名称 | 证券代码 | 证券名称 | | 600025 | 华能水电 | 600118 | 中国卫星 | | 600062 | 华润双鹤 | 600415 | 小商品城 | | 600141 | 兴发集团 | 600418 | 江淮汽车 | | 600383 | 金地集团 | 600489 | 中金黄金 | | 600487 | 亨通光电 | 600 ...

上海证券交易所 中证指数有限公司 2023年11月24日 附件：部分指数样本调整名单 根据指数规则，经指数专家委员会审议，上海证券交易所与中证指数有限公司决定调整上证50、上 证180、上证380、科创50等指数样本，于2023年12月8日收市后生效。其中上证50指数更换5只样本，上 证180指数更换18只样本，上证380指数更换38只样本，科创50指数更换1只样本。上述指数样本调整名 单和备选名单见附件。 为便于投资者获取指数样本调整信息，对于本次定期调整的其他指数，投资者后续可直接通过中证 指数有限公司官网（www.csindex.com.cn）右上角搜索栏检索指数代码进入各指数页面，并在右侧相关 资料中查阅"拟生效样本"。 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥8,225,433,605.49, representing a decrease of 8.28% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was ¥186,852,024.02, an increase of 22.65% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥238,222,209.75, up 58.85% from the previous year[4]. - Basic earnings per share for Q3 2023 was ¥0.0725, reflecting a growth of 22.88% year-on-year[4]. - The net profit for Q3 2023 was CNY 1,489,456,704.40, a decrease from CNY 1,558,784,901.19 in Q3 2022, representing a decline of approximately 4.4%[17]. - The total profit for Q3 2023 was CNY 1,909,710,596.36, compared to CNY 1,858,685,920.06 in Q3 2022, indicating a growth of about 2.8%[17]. - The operating profit for Q3 2023 was CNY 1,912,579,458.96, slightly higher than CNY 1,875,209,265.23 in Q3 2022, showing an increase of approximately 2.4%[17]. - The total comprehensive income for Q3 2023 was CNY 1,496,651,119.16, down from CNY 1,585,282,325.66 in Q3 2022, representing a decrease of approximately 5.6%[18]. Cash Flow - The net cash flow from operating activities for the year-to-date period reached ¥3,924,570,676.43, a significant increase of 1,820.89% compared to the same period last year[4]. - The net cash flow from operating activities for Q3 2023 was ¥3,924,570,676.43, a significant improvement from a net outflow of ¥228,054,074.04 in Q3 2022[20]. - Total cash inflow from investment activities was ¥2,790,656,816.54, compared to ¥2,702,799,717.04 in the same period last year[20]. - The net cash flow from investment activities showed a loss of ¥1,949,288,105.46, an improvement from a loss of ¥3,649,689,361.48 in Q3 2022[20]. - Cash inflow from financing activities totaled ¥6,086,231,876.96, down from ¥12,409,939,796.56 in Q3 2022[20]. - The net cash flow from financing activities was negative at -¥1,976,766,556.51, compared to a positive flow of ¥4,166,008,995.66 in the previous year[20]. - The total cash and cash equivalents at the end of Q3 2023 amounted to ¥7,881,683,236.20, an increase from ¥6,377,775,854.83 at the end of Q3 2022[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥52,293,310,406.08, a decrease of 4.02% from the previous year-end[4]. - The total assets decreased to ¥50,278,681,050.20 from ¥52,385,798,596.69, a reduction of 4%[15]. - The total liabilities decreased to ¥29,962,565,922.47 from ¥33,542,017,842.73, a decline of 10.5%[15]. - The company reported a total asset value of ¥52,385,798,596.69 as of January 1, 2023, reflecting an increase from ¥52,293,310,406.08 at the end of 2022[23]. - The total liabilities rose from ¥33,450,764,548.03 at the end of 2022 to ¥33,542,017,842.73 as of January 1, 2023[23]. Equity - The equity attributable to shareholders at the end of the reporting period was ¥9,133,813,548.67, an increase of 7.76% compared to the previous year-end[4]. - The company’s total equity increased to ¥20,316,115,127.73 from ¥18,843,780,753.96, reflecting a growth of 7.8%[15]. - The company’s total equity attributable to shareholders increased slightly from ¥9,133,813,548.67 at the end of 2022 to ¥9,135,864,452.50 as of January 1, 2023[23]. Investment and Financing - The company increased its long-term borrowings by 82.45%, reaching ¥8,995,465,306.31 due to new long-term loans[7]. - The company reported a significant increase in long-term borrowings, which rose to ¥8,995,465,306.31 from ¥4,930,271,374.05, an increase of 82%[15]. - Interest income decreased by 69.90% to ¥8,301,218.20 compared to ¥27,574,921.59 in the same period last year due to the contraction of microloan business[8]. - Investment income fell by 59.00% to ¥175,858,733.30 from ¥428,963,478.75, primarily due to high investment returns from joint ventures in the previous year[8]. Impairment Losses - The company’s subsidiaries reported a significant reduction in credit impairment losses by 76.63% to -¥27,349,016.51, compared to -¥117,032,081.55 in the previous year[8]. - The company’s subsidiaries reported an increase in asset impairment losses by 228.15% to -¥69,447,034.73, attributed to increased inventory write-downs due to market conditions[8]. Other Agreements and Projects - The company completed the transfer of 59.469 million shares of Shenzhen Dafu Pharmaceutical Co., Ltd. at ¥4.38 per share to Hangzhou Yunbai Pharmaceutical Technology Co., Ltd.[11]. - The company signed a supplementary agreement for the urban renewal project in Longgang District, Shenzhen, focusing on "urban renewal + benefit coordination"[11]. - A joint venture agreement was amended to adjust the construction site for a new energy lithium battery anode material project in Indonesia[11].

中国宝安集团股份有限公司董事局 关于下属子公司申请公开发行股票并在北交所上市 辅导备案的提示性公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中国宝安集团股份有限公司（以下简称"公司"）控股子公司张家港友诚新能 源科技股份有限公司（以下简称"友诚科技"）为全国中小企业股份转让系统挂牌 企业，证券简称：友诚科技，证券代码：873087。友诚科技于 2023 年 9 月 20 日 向中国证券监督管理委员会江苏监管局提交了向不特定合格投资者公开发行股 票并在北京证券交易所上市的辅导备案材料，辅导机构为东吴证券股份有限公司。 具体内容请详见友诚科技 2023 年 9 月 22 日在全国股转公司官网披露的《申请公 开发行股票并在北交所上市辅导备案公告》（公告编号：2023-049）。敬请广大投 资者注意投资风险。 特此公告 证券代码：000009 证券简称：中国宝安 公告编号：2023-035 中国宝安集团股份有限公司 二〇二三年九月二十三日 1 ...

证券代码：000009 证券简称：中国宝安 公告编号：2023-034 中国宝安集团股份有限公司 关于马应龙股份解除质押及再质押的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中国宝安集团股份有限公司（以下简称"中国宝安"或"本公司"）于 2023 年 9 月 19 日在中国证券登记结算有限责任公司与中国银行股份有限公司深圳罗 湖支行办理了本公司持有的马应龙药业集团股份有限公司（以下简称"马应龙"） 10,000,000 股无限售流通股解除质押手续，并在同日将 10,000,000 股无限售流通 股再次质押给中国银行股份有限公司深圳罗湖支行，具体事项如下： | 股东 | 是否为控股股东 | 本次解除质押 | 占本公司所 | 占马应 | | | 解除 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 或第一大股东及 | 股份数量 | 持股份比例 | 龙总股 | 起始日 | | 日期 | | 质权人 | | | 其一致行动人 | （股） | | 本比例 | ...

中国宝安集团股份有限公司 2023 年半年度报告全文 2023 年半年度报告 2023 年 08 月 1 中国宝安集团股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事局、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人陈政立、主管会计工作负责人贺德华及会计机构负责人(会计 主管人员)吴海涛声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事局会议。 公司已在本报告中详细描述公司存在的风险因素，敬请查阅第三节管理层 讨论与分析中关于公司面临的风险和应对措施部分内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 中国宝安集团股份有限公司 2023 年半年度报告全文 目录 | --- | --- | --- | |-------|-----------------------------------------------|-------| | | | | | | 第一节 重要提示、目录和释义 | | | | 第二节 公司简 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥8,228,499,170.23, representing a 44.78% increase compared to ¥5,683,423,572.87 in the same period last year[3] - The net profit attributable to shareholders for Q1 2023 was ¥239,346,190.45, up 44.94% from ¥165,134,224.14 in the previous year[3] - The basic earnings per share for Q1 2023 was ¥0.0928, reflecting a 45.00% increase from ¥0.0640 in the same period last year[3] - The net profit for Q1 2023 was CNY 466,266,526.51, an increase from CNY 450,961,686.24 in the same period last year, representing a growth of approximately 3%[15] - The total revenue from operating activities reached CNY 8,474,847,685.66, compared to CNY 4,512,263,714.73 in Q1 2022, indicating a significant increase of about 88%[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥1,727,503,958.72, a significant increase of 464.39% compared to -¥474,078,022.77 in Q1 2022[3] - The cash and cash equivalents net increase for Q1 2023 was ¥1,036,730,692.66, a 267.47% rise from -¥619,058,999.24 in the same period last year[7] - The company's cash and cash equivalents at the end of Q1 2023 amount to ¥10,070,952,149.69, a decrease from ¥10,531,615,227.89 at the beginning of the year[11] - The cash flow from operating activities generated a net amount of CNY 1,727,503,958.72, a turnaround from a negative cash flow of CNY -474,078,022.77 in Q1 2022[17] - The company experienced a net cash outflow from investing activities of CNY -727,360,643.47, an improvement from CNY -1,619,628,525.05 in the previous year[18] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥51,389,870,782.13, a decrease of 1.73% from ¥52,293,310,406.08 at the end of the previous year[3] - Non-current liabilities totaled ¥10,687,425,012.07, an increase from ¥9,258,839,983.57 year-over-year[13] - The company's cash and cash equivalents decreased to ¥6,657,890,346.84 from ¥8,315,457,905.76, a decline of 20%[13] - Total current assets are reported at ¥33,509,545,238.03, down from ¥34,986,065,478.91 at the start of the year[11] - Accounts receivable stand at ¥6,067,883,624.75, compared to ¥6,372,524,173.95 at the beginning of the year, indicating a decrease[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 226,236, with the top 10 shareholders holding a combined 40.17% of shares[8] - The largest shareholder, Shenzhen Chengxing Investment Co., Ltd., holds 16.55% of shares, totaling 426,868,042 shares[8] - The total number of shares held by the largest three shareholders is 448,710,475, representing 17.40% of the total shares[9] Investment and Expenses - The company reported a significant increase in investment income of 287.32%, amounting to ¥276,739,569.40, compared to ¥71,450,432.04 in the previous year[6] - The company experienced a 56.63% increase in operating costs, totaling ¥6,703,674,818.06, compared to ¥4,279,926,891.25 in Q1 2022[6] - Research and development expenses rose to ¥312,568,379.95, compared to ¥254,263,898.68 in the previous year, marking an increase of 23%[14] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[10] - There is no indication of any mergers or acquisitions in the current financial report[10] - The total assets impairment loss for Q1 2023 was CNY -43,011,591.77, contrasting with a gain of CNY 3,545,680.11 in Q1 2022[15] - The company reported a total comprehensive income of CNY 443,624,965.03 for Q1 2023, slightly up from CNY 442,967,681.48 in the same quarter last year[16]

Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.35 CNY per 10 shares to all shareholders, based on a total of 2,579,213,965 shares[2]. - The company distributed a cash dividend of ¥0.35 per 10 shares, totaling ¥90,272,488.77, which represents 100% of the total profit distribution[114][115]. - The company reported a total distributable profit of ¥395,102,959.66 at the end of the reporting period[115]. Financial Performance - The company's operating revenue for 2022 was ¥31,998,720,906.66, representing an increase of 82.29% compared to ¥17,553,419,112.71 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥1,156,580,360.59, an increase of 11.68% from ¥1,035,599,088.75 in 2021[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥680,810,615.67, up 75.72% from ¥387,441,388.95 in 2021[12]. - The net cash flow from operating activities for 2022 was ¥290,476,146.61, a significant improvement from a negative cash flow of ¥279,272,690.50 in 2021, marking a 204.01% increase[12]. - The total assets at the end of 2022 were ¥52,293,310,406.08, a 41.05% increase from ¥37,073,195,202.73 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥9,133,813,548.67, reflecting a 14.17% increase from ¥8,000,289,198.35 at the end of 2021[13]. - The company achieved a weighted average return on equity of 13.49% in 2022, slightly down from 13.90% in 2021[12]. Business Operations and Strategy - The company reported significant changes in its business scope, including investments in new materials and high-tech industries since 2014[10]. - The company has undergone several changes in its business operations, including real estate development and modern biomedicine projects[10]. - The company is focused on high-tech industries, including new energy materials and electric vehicles, aligning with national strategic initiatives for industry upgrades[20]. - The company plans to continue developing new technologies and expanding its market presence in strategic emerging industries, enhancing its operational capabilities[20]. - The company aims to develop functional health products leveraging existing technology, brand, and channels, while continuously innovating and upgrading its business model[22]. Research and Development - The company reported a significant increase in R&D expenses, totaling ¥1,508,490,891.16, which is an 86.90% increase compared to ¥807,125,218.97 in 2021[49]. - The number of R&D personnel increased to 1,557 in 2022, up 24.86% from 1,247 in 2021[54]. - R&D investment amounted to ¥1,521,111,792.01 in 2022, representing an 87.36% increase from ¥811,884,198.00 in 2021[56]. - The proportion of R&D investment to operating revenue rose to 4.75% in 2022 from 4.63% in 2021, an increase of 0.12%[56]. Environmental Compliance - The company strictly adheres to environmental protection laws and industry standards in its production and operational activities[125]. - The company and its subsidiaries are classified as key pollutant discharging units by environmental protection authorities[125]. - The company has obtained pollution discharge permits for its subsidiaries, ensuring compliance with environmental regulations[126]. - The total COD emissions for 2022 were 0.038 tons, with ammonia nitrogen at 0.0001 tons and phosphate at 0.0005 tons[127]. - The company has implemented measures to ensure that emissions meet the required standards after treatment[128]. Governance and Management - The company maintains a governance structure compliant with legal regulations, ensuring independent operation without major shareholder interference[86]. - The company has established independent financial and operational systems, ensuring no asset misappropriation by major shareholders[86]. - The company has a diverse board with members holding various professional qualifications, including registered accountants and legal professionals[93]. - The company has maintained stability in its leadership with no reported changes in directors or senior management during the reporting period[90]. Market and Industry Challenges - The real estate market faced unprecedented challenges in 2022, but policies are being implemented to stabilize and support the sector[23]. - The biopharmaceutical sector is under pressure from regulatory changes and the need for new business development to ensure sustainable growth[81]. - The company faces risks related to industry policies, technological obsolescence, and supply chain dynamics, with measures in place to mitigate these risks[80]. Legal and Compliance Issues - The total amount involved in the lawsuit against Shenzhen Yuntong Logistics Co., Ltd. and others is approximately 670.72 million RMB, with a claim for full compensation of this amount[145]. - The court has taken preservation measures on assets valued at approximately 670.72 million RMB belonging to the defendants, but the lawsuit has not yet been concluded[145]. - There were no significant penalties or rectifications reported during the reporting period[147]. Shareholder Structure - The company has no controlling shareholder or actual controller since 2009, with the top two shareholders holding 8.34% and 6.95% respectively[10]. - The largest shareholder holds 16.04% of the company, with the second and third largest shareholders holding 15.04% and 5.92% respectively, indicating a diversified ownership structure[86]. - The total number of ordinary shareholders at the end of the reporting period was 226,073[165]. Financial Instruments and Debt Management - The company has issued a total of three bonds, with a total amount raised of CNY 2.05 billion, including CNY 1 billion for the 2017 bond, CNY 300 million for the 2021 bond, and CNY 750 million for the 2022 bond[174][176]. - The company has maintained its debt repayment mechanisms and plans without any changes during the reporting period, ensuring investor rights are protected[178]. - The company has not reported any overdue bonds during the reporting period, indicating a stable financial position[178]. Community Engagement and Social Responsibility - The company donated over 90 million yuan in total for social responsibility initiatives, including 15.6 million yuan worth of medicines to impoverished areas in 2022[138]. - The company organized 68 health events, benefiting over 110,000 community residents with free health check-ups[138]. - The company has committed to ongoing support for rural revitalization efforts, including cash donations and product purchases[138].